The discovery of these immunosuppressive mechanisms has prompted thinking about the possibility of targeting TIGIT in cancer therapy, and while the main approach has been the development of monoclonal antibodies, there are some less-investigated approaches, such as the use of small-molecule inhibitors. The gene discussed is TIGIT; the disease is cancer.